Altre lingue GC Biopharma Corp.

Azioni

A006280

KR7006280002

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 09/05/2024			Variaz. 5gg	Var. 1 gen.
114.100 ^KRW	-1,55%		-0,17%	-9,08%

03/05	Green Cross amplia la perdita del primo trimestre, ma le vendite aumentano del 2%.	MT
20/03	GC Biopharma Corp. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Green Cross Widens Q1 Loss, Sales Inch Up 2%	03/05
GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	18/12
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea	01/12
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
GC Biopharma Applies for MFDS Approval	06/11
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases	12/10/23
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Green Cross's Net Income Plunges in Q2	02/08/23
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt	21/07/23
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent	19/07/23
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia	02/06/23
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Green Cross Swings to Loss in Q1	03/05/23
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	01/03/23
GC Biopharma Receives WHO Pre-Qualification for BARYCELA	20/02/23
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea	09/02/23
Curevo, Inc. announced that it has received $22.000002 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, GC Biopharma Corp. and other investors	21/11/22
Green Cross Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Curevo, Inc. announced that it expects to receive $26.000003 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, Green Cross Corporation	09/11/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue GC Biopharma Corp.

Azioni

A006280

KR7006280002

Altre lingue

Filtri